Otsuka Completes $1.23B Buyout of Transcend Therapeutics

PRINCETON – Otsuka America, the U.S. subsidiary of Otsuka Pharmaceutical Co., Ltd., announced that it has completed its acquisition of Transcend Therapeutics, a New York biotechnology company developing rapid-acting treatments for neuropsychiatric disease. First disclosed in March, the deal makes Transcend a wholly owned subsidiary of Otsuka America and folds the company’s lead candidate, TSND-201, into one of the world’s larger privately held pharmaceutical portfolios.

Per official release, Otsuka paid $700 million to Transcend shareholders at closing, with up to $525 million more available in contingent payments tied to future commercial sales milestones, bringing total potential consideration to roughly $1.225 billion.

TSND-201 is Transcend’s proprietary formulation of methylone, engineered without activity at the 5-HT2A receptor, the site associated with hallucinogenic effects in classic psychedelics. That design choice positions the drug outside the clinical and regulatory complexity tied to dosing protocols requiring supervised hallucinogenic sessions. The FDA granted TSND-201 Breakthrough Therapy designation in 2025 after the Phase 2 IMPACT-1 trial showed statistically significant symptom reduction against placebo, with effects measurable within ten days. Those results were later published in JAMA Psychiatry.

Tarek Rabah, president and CEO of Otsuka North America Pharmaceutical Business, framed the deal as an extension of the company’s existing central nervous system portfolio and its longer-running commitment to serious mental illness. Transcend co-founder and CEO Blake Mandell called the acquisition a new chapter for the company’s PTSD-focused mission.

The Otsuka-Transcend transaction registers as confirmation that large pharmaceutical buyers will still commit nine figures upfront for late-stage assets carrying FDA Breakthrough status, even when the underlying chemistry traces back to a controlled substance. TSND-201’s deliberate avoidance of 5-HT2A activity looks less like an incidental design feature and more like a commercial strategy. A compound positioned to deliver psychedelic-adjacent therapeutic effects without the supervised-dosing infrastructure that has slowed commercialization elsewhere in the sector. Buyers evaluating future deals in this space may find that distinction carries more weight than headline valuation figures.